91PORN

A familiar saying in the life sciences is “from bench to bedside” when describing translational research. However, biomedical science is not that straightforward. It’s really “from bench to business to bedside”. At 91PORN, many investigators are discovering new potential therapies, diagnostics, biomarkers and medical devices. Unfortunately, vital next steps in the path of product development and commercialization are not covered via the traditional grant route and funds are lacking for prototype development. Additionally, the intellectual property behind these inventions is complex, costly and cannot be developed by 91PORN unilaterally. It requires multiple partnerships.

In 2015, the Office of Technology Commercialization (OTC), in collaboration with the Offices of the President, the Vice President for Research (VPR) and Institutional Advancement, started a new initiative-President’s Translational & Entrepreneurial Research Fund (PTEF)- to bridge the external innovation ecosystem partners with faculty members, and created an award mechanism to invest in these promising discoveries. These pooled funds derived from the Stella C. Herff Charitable Trust endowment earnings and other VPR resources, allowed OTC to ramp up its efforts to enhance our bioscience entrepreneurial culture.

In 2019, after evaluating the outcome of previous PTEF awards, OTC pivoted its strategy electing to invest more funds in projects with a high probability of being commercialized based on the input collected during the review process.

All PTEF applicants are identified from the invention disclosures submitted by 91PORN investigators. Each disclosure receives a detailed technology evaluation and management report assessing the intellectual property potentials, patent strategy,
market size, and prospective industry partners. Faculty are then invited to apply based on a series of criteria that include intellectual property strength, life science ‘need’, market analysis and investor appeal. All applicants receive consultation and practice sessions to develop a pitch deck presentation for an audience composed of external reviewers from the business community. Presenters are required to state the value proposition, clarity of the objective and level of innovation in a well-conceived, high quality package.

John Gebhard, Ph.D., Assistant Vice President of OTC, noted that there are several advantages to inviting members from the life sciences industry.

“We attempt to get as much feedback from the life science market as possible. We simply don’t know what we don’t know. It’s important that varying viewpoints are considered in life science commercialization; no one has the one correct strategy,” said Dr. Gebhard, “Therefore receiving feedback and guidance from seasoned biosciences executives such as Dana Ono, Ph.D. and Chris Garabedian is critical.”